What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders [Yahoo! Finance]
Protara Therapeutics, Inc. (TARA)
Company Research
Source: Yahoo! Finance
This inclusion can expand Protara Therapeutics' exposure to institutional investors and may influence trading volume as index-tracking funds adjust their holdings. We'll explore how joining a widely followed index could shape Protara Therapeutics' investment narrative and investor participation. Find companies with promising cash flow potential yet trading below their fair value What Is Protara Therapeutics' Investment Narrative? For those interested in Protara Therapeutics, the investment story centers on the potential of its pipeline, particularly TARA-002 in bladder cancer and IV Choline Chloride in nutrition support, paired with visible leadership hires and recent inclusion in global indices. The company's steep losses, zero revenue, and history of shareholder dilution speak to the classic early-stage biotech profile, where catalysts like clinical trial milestones and regulatory visibility matter most. The recent addition to the S&P Global BMI Index raises the prospect of
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Announces Pricing of $75 Million Public OfferingGlobeNewswire
- Protara Announces Proposed Public Offering [Yahoo! Finance]Yahoo! Finance
- Protara Announces Proposed Public OfferingGlobeNewswire
- Protara Therapeutics: End Of 2025 Proving Eventful Indeed [Seeking Alpha]Seeking Alpha
- Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
TARA
Earnings
- 11/10/25 - Beat
TARA
Sec Filings
- 12/4/25 - Form 424B5
- 12/3/25 - Form 8-K
- 11/19/25 - Form 8-K
- TARA's page on the SEC website